drugset / Trial / NCT00623233
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To determine how long Gemcitabine and Bevacizumab will stop the cancer from growing in patients with advanced breast cancer.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 2500 mg/m2 | Intravenous |